QUEBEC CITY, Aug. 13 /CNW/ - Medicago Inc. (TSX-V: MDG) today announced
that it will be presenting an update of its development of H5N1 vaccines
generated from plant-made VLPs and unique technology platform, at the Targeted
Immunotherapeutics and Vaccine Summit. This conference will be held from
August 13-15, 2008, at the Royal Sonesta Hotel, Cambridge, Massachusetts.
Manon Couture, Ph.D., Project Leader, Product Development and Innovation
will deliver a presentation on "Innovative Influenza Virus-Like Particles
Provides Protection against an H5N1 Challenge" in a session entitled
"Innovating Vaccine Development," on Thursday August 14, 2008 at 10:45 a.m.
Additional information about the Targeted Immunotherapeutics and Vaccines
Summit, including the full scientific program, can be viewed at
Medicago is committed to provide highly effective and affordable vaccines
based on proprietary Virus-Like Particle (VLP) and manufacturing technologies.
Medicago is developing VLP vaccines to protect against H5N1 pandemic
influenza, using a transient expression system which produces recombinant
vaccine antigens in non-transgenic plants. This technology has potential to
offer advantages of speed and cost over competitive technologies. It could
deliver a vaccine for testing in about a month after the identification and
reception of genetic sequences from a pandemic strain. This production time
frame has the potential to allow vaccination of the population before the
first wave of a pandemic strikes and to supply large volumes of vaccine
antigens to the world market. Additional information about Medicago is
available at www.medicago.com.
This press release contains forward-looking statements which reflect
Medicago's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. Medicago disclaims any obligation to
update these forward-looking statements.
The TSX Venture Exchange assumes no responsibility for the content or
accuracy of this press release
For further information:
For further information: Medicago, Inc., Andy Sheldon, President and
CEO, (418) 658-9393; Investor relations, The Equicom Group Inc., Arianna
Vanin, (514) 844-4680, firstname.lastname@example.org